LEADER 01867oam 2200529zu 450 001 9910830042303321 005 20210807003058.0 010 $a3-527-61825-2 035 $a(CKB)1000000000687237 035 $a(SSID)ssj0000353927 035 $a(PQKBManifestationID)11270484 035 $a(PQKBTitleCode)TC0000353927 035 $a(PQKBWorkID)10290549 035 $a(PQKB)10499736 035 $a(EXLCZ)991000000000687237 100 $a20160829d2000 uy 101 0 $aeng 181 $ctxt 182 $cc 183 $acr 200 00$aCarbohydrates in chemistry and biology 210 31$a[Place of publication not identified]$cWiley VCH$d2000 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a3-527-29511-9 327 $apt. 1. Chemistry of saccharides, v. 1. Chemical synthesis of glycosides and glycomimetics -- v.2. Enzymatic synthesis of glycosides and carbohydrate receptor interaction -- pt. 2. Biology of saccharides, v. 3. Biosynthesis and degradation of glycoconjugates -- v.4. Lectins and saccharide biology (v.1-2 comprise pt.1; v.3-4 comprise pt.2). 606 $aCarbohydrates 606 $aCarbohydrates 606 $aChemicals and Drugs 606 $aAnimal Biochemistry$2HILCC 606 $aHuman Anatomy & Physiology$2HILCC 606 $aHealth & Biological Sciences$2HILCC 615 0$aCarbohydrates 615 2$aCarbohydrates 615 2$aChemicals and Drugs 615 7$aAnimal Biochemistry 615 7$aHuman Anatomy & Physiology 615 7$aHealth & Biological Sciences 676 $a572/.56 702 $aSina’$b Pierre 702 $aSinačy$b Pierre 702 $aHart$b Gerald W 702 $aErnst$b Beat 801 0$bPQKB 906 $aBOOK 912 $a9910830042303321 996 $aCarbohydrates in chemistry and biology$91974440 997 $aUNINA LEADER 02837nam 2200469z- 450 001 9910346745603321 005 20210212 035 $a(CKB)4920000000094258 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/58584 035 $a(oapen)doab58584 035 $a(EXLCZ)994920000000094258 100 $a20202102d2017 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRole of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies 210 $cFrontiers Media SA$d2017 215 $a1 online resource (202 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-320-0 330 $aThis Research Topic was focused on provision of novel medical technologies worldwide keeping in mind financial sustainability challenge. An exemplary area certainly are oncology pharmaceuticals where prices have increased 10-fold in recent years leading to concerns on affordability. The objective of this collection of studies was to reveal some of the hidden underlying causes of unequal access to the medicines. Another core issue is the growing proportion of out-of-pocket health spending in many world regions. In line with the joint efforts of the editors and authors we received an exceptionally high response worldwide. This E-Book attracted a total of 37 self-standing research submissions out of which 32 ultimately passed external peer review and got published. Base affiliations of the authors spread across academia, pharmaceutical and medical device industry, governmental authorities and clinical medicine. Their home institutions were situated in fifteen different countries inclusive of Japan, Israel, Russia, USA, Germany, Italy, Netherlands, Austria, Spain, Malta, Serbia, Poland, Bulgaria, Hungary and Malaysia. We frankly believe that authors succeeded to cover important literature gaps referring to these world regions. We solicit global professional audience to put our efforts to the test and read this contribution to the health economics literature. 606 $aPharmacology$2bicssc 610 $acost 610 $aDecision Making 610 $aEmerging Markets 610 $aHealth Economics 610 $aHealth expenditure 610 $ahealth investment 610 $ahealth policy 610 $ahealth technology assessment 610 $amedical technology 610 $areimbursement 610 $aResource Allocation 615 7$aPharmacology 700 $aTetsuji Yamada$4auth$01329316 702 $aMihajlo (Michael) Jakovljevic$4auth 906 $aBOOK 912 $a9910346745603321 996 $aRole of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies$93039417 997 $aUNINA